R&D, Scientific & Medical Writing
- Supported a global pharmaceutical company in the writing of a briefing book for a pre-BLA meeting for NSCLC indication, 2021-present.
- German company in bioinformatics and data analytics in cancer, 2016-present: abstracts, papers
- Finish preclinical CRO, 2017-present: assistance in writing reports, advice on internal projects, member Steering Group
- LibraMedicina, Inc. Japan, 2007-present: search potential licensees for anticancer drugs in preclinical stage
- Meeting Report CDDF Multi-stakeholder workshop on Impact of the Microbiome on Cancer Growth and Therapy, February 2019
- Meeting Report CDDF 10th Alpine Conference on Current and Future Challenges of Innovative Oncology Drugs Development, 2018
- Meeting Report on the CDDF Multi-stakeholder Workshop Innovation in Oncology Clinical Trial Design, 2017 and the subsequent paper 2019, https://doi.org/10.1016/j.ctrv.2019.01.001
- Australian preclinical CRO, 2015-2016: report writing efficacy studies oncology drugs
- German biotech, 2015; modification Investigator's Brochure oncology drug
- German global Health company 2014: modification draft manuscript on research project and assistance non-clinical development future therapeutic agents
- Komipharm, Korea and Rephartox, The Netherlands, 2001-2007: design, execution and project management of discovery and preclinical development arsenic anticancer compound KML001:
- Recent publications
- Verweij J, Hendriks HR, Zwierzina H, on behalf of the Cancer Drug Development Forum. Innovation in Oncology Clinical Trial Design. Cancer Treatment Reviews 2019;74:15-20, https://doi.org/10.1016/j.ctrv.2019.01.001
- Peters GJ, Govaerts A-S, Hendriks HR, for the EORTC-PAMM group. The Role of Pharmacology in Anticancer Drug Development. ADMET & DMPK 2018;6:4-14
- Hendriks et al, Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds inititative, British Journal of Cancer 2017;117:195-202
- Quandt et al, Implementing liquid biopsies into clinical decision making for cancer immunotherapy, Oncotarget 2017;8:48507-48520
- Phillips et al, Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer, Expert Opinion on Drug Metabolism &Toxicology 2017;13:783-791
- Recent lectures
- Hendriks HR. Preclinical drug development in oncology. Educational lecture, Finnish prclinical CRO, December 2019
- Hendriks HR. Drug development, after the NCI-compounds initiative. Educational course: preclinical and early-phase clinical pharmacology. 40th EORTC-PAMM Winter meeting, Verona, 6 February, 2019.
- Hendriks HR. New Types of Clinical Studies. Educational course: Preclinical and early-phase clinical pharmacology. 40th EORTC-PAMM Winter meeting, Verona, 6 February, 2019.
- Hendriks HR. Pharmacology directed strategies in anticancer drug development, a viable approach for academia? Turku Cancer Research Society & Western Cancer Centre FICAN West, Cancer Seminar Series, Turku, Finland, 4 September 2018.
